Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid.Antimicrobial agents and chemotherapy · 2020
   Trial
2. Highly fluorescent method for ultra-sensitive estimation of delafloxacin in human plasma: greenness assessment.BMC chemistry · 2026
   Article
3. The Intersection of Antimicrobial Stewardship, the Pharmaceutical Industry, and the Federal Legislature.Open forum infectious diseases · 2022
   Review
4. It's about the patients: Practical antibiotic stewardship in outpatient settings in the United States.Frontiers in medicine · 2022
   Review
5. Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.Antimicrobial agents and chemotherapy · 2019
   Article

Corrections and comments

• Comment on
  A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as